PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of pembrolizumab for locally advanced uterine cervical cancer, and durvalumab and olaparib for advanced or recurrent endometrial cancer in Japan
本文未提供摘要，请点击“查看全文”查看完整内容。